Influence of Implant Insertion Torque on Post-Surgical Marginal Bone Stability
NCT ID: NCT07019480
Last Updated: 2025-06-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
150 participants
OBSERVATIONAL
2025-01-01
2035-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Implant Insertion Torque and Primary Stability
NCT03222219
Influence of Thickness of the Peri-implant Soft Tissue on Marginal Bone Remodeling
NCT03077880
Analysising the Marginal Bone Loss, Torque and Implant Stability Placed in Bone and Tissue Level Dental Implants
NCT07288606
Impact of Abutment Screw Torque on Marginal Bone Loss
NCT07234552
Evaluation of Implant Stability Changes in Sites Prepared with Different Osseodensification Techniques: a Prospective Observational Clinical Study
NCT06679894
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Enrollment Procedure: All patients meeting the inclusion and exclusion criteria will be enrolled in the study after receiving the Information Sheet and providing written informed consent.
Pre-surgical planning will be performed using a CBCT scan with or without the aid of dedicated image reconstruction software. A preoperative periapical radiograph will also be taken using a customized Rinn-type film holder for each patient, with the aid of a silicone key.
Surgical phase: After local anesthesia with 4% articaine containing 1:100,000 epinephrine, a minimally invasive full-thickness mucoperiosteal flap will be elevated to visualize the crest anatomy. The height of the supracrestal soft tissue will be measured using a dedicated probe (SSL, Medesy, Maniago, Italy) and categorized as thin (\<2.5 mm), medium (2.5-3.5 mm), or thick (\>3.5 mm).
Implant site preparation will be carried out using a dedicated surgical kit (Anyone, Megagen, Gyeongbuk, South Korea). The implant (Anyone, 4.0×8.5 mm) will then be placed at crestal level, with torque values recorded throughout the entire insertion process using a surgical motor set to 30 rpm (Implantmed, W\&H, Burmoos, Austria). The maximum torque will be limited to 80 Ncm.
If the maximum torque is insufficient to complete insertion, the implant will be removed and the site will be further prepared using the next drill in the sequence.
After crestal-level placement, Patients will be prescribed an NSAID (ibuprofimplant stability (ISQ) will be measured in the mesio-distal, disto-mesial, bucco-lingual, and linguo-buccal directions using a resonance frequency analysis device (Osstell Beacon, Osstell, Göteborg, Sweden) with a single-use magnetic peg specific to the implant (SmartPeg Type 07, Osstell, Göteborg, Sweden). Calibration of the device must be verified prior to each patient procedure using an implant secured in a resin block.
The flap will be closed using non-resorbable monofilament sutures, and the implant will be submerged (two-stage protocol). A periapical radiograph will be taken at this point (T0) using the previously described customized Rinn-type holder. en 600 mg, as needed) and instructed to rinse with 0.2% chlorhexidine mouthwash for two minutes, three times per day, starting on the second postoperative day.
Sutures will be removed 7-10 days after surgery.
Post-surgical follow-ups: After three months of healing (T1), a periapical radiograph will be taken using the previously described customized holder, and a second-stage surgery will be performed to uncover the implant. Following ISQ measurement as previously described, a definitive transmucosal abutment of appropriate length and diameter (OCTA, Megagen, Gyeongbuk, South Korea) will be connected. After a four-week healing period, an abutment-level impression will be taken for the fabrication of the final prosthesis, which may be either a single screw-retained metal-ceramic crown or a screw-retained bridge.
Periapical radiographic follow-ups will be performed as described above at prosthesis delivery and at 6 months, 1 year, 3 years, and 5 years post-loading to assess marginal bone stability.
Radiographic Measurements: All radiographs will be taken using identical radiographic device settings (60 kV, 7 mA). Peri-implant bone levels (PBL) will be measured at T0 and T1 as the linear distance between the implant platform and the bone crest at the mesial and distal aspects of each implant. A positive value will be assigned when the bone crest is coronal to the implant platform, while a negative value will be recorded when the first bone-to-implant contact is apical to the implant platform.
The difference in PBL between T0 and T1 will represent marginal bone loss if PBL\_T1 \< PBL\_T0, and marginal bone gain if PBL\_T1 \> PBL\_T0. Measurements will be calibrated according to the known implant diameter and length.
Any radiograph showing distortion and/or other quality issues must be immediately retaken.
All measurements will be performed by two blinded examiners using image analysis software (ImageJ 1.52a, National Institutes of Health, Bethesda, MD, USA) on a 24-inch medical-grade monitor. Each measurement will be repeated three times at three different time points, as proposed by Gomez-Roman and Launer.
Examiner calibration will be carried out on a sample of ten radiographs not included in the study. The Cohen's kappa coefficient (k) will be calculated by a third investigator to assess intra-examiner and inter-examiner agreement.
Statistical Analysis: Descriptive statistics will be used to summarize the baseline characteristics of the study population. The relationship between insertion torque and marginal bone loss will be assessed using regression models, adjusting for potential confounding variables. Repeated measures ANOVA will be used to analyze ISQ changes over time. A p-value \<0.05 will be considered statistically significant. Data analysis will be performed using SPSS Statistics v25.0 (IBM Corp., Armonk, NY, USA).
Sample Size Calculation: The sample size was calculated based on a previously published study (Marconcini S, Longitudinal analysis on the effect of insertion torque on delayed single implants: A 3-year randomized clinical study. Clin Implant Dent Relat Res. 2018;20(3):322-332.), which reported a one-year failure rate of 1.72% (1/58) in the low insertion torque group (\<50 Ncm) and 3.45% (2/58) in the high insertion torque group (≥ 50 Ncm). A 1:1 allocation ratio was considered, with a significance level of 0.01 and statistical power of 90%. The minimum required sample size was 68 implants (34 per group). To compensate for potential drop-outs and to allow for repeated measures analysis, 150 implants will be placed across 10 clinical centers (15 implants per center). Each patient may contribute up to 3 implants.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
cohort
implant insertion with recorded torque and stability values
implant insertion
Following local anesthesia (articaine 4% with epinephrine 1:100,000), a minimally invasive full-thickness flap will be elevated. Implant site preparation will be performed with twist drills and the implant will be inserted. Implant stability (ISQ) will be measured in the mesio-distal, disto-mesial, bucco-lingual, and linguo-buccal directions using a resonance frequency analysis device (Osstell Beacon, Osstell, Göteborg, Sweden) with a single-use magnetic peg specific to the implant (SmartPeg Type 07, Osstell, Göteborg, Sweden).
The flap will be closed using non-resorbable monofilament sutures, and the implant will be submerged (two-stage protocol).
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
implant insertion
Following local anesthesia (articaine 4% with epinephrine 1:100,000), a minimally invasive full-thickness flap will be elevated. Implant site preparation will be performed with twist drills and the implant will be inserted. Implant stability (ISQ) will be measured in the mesio-distal, disto-mesial, bucco-lingual, and linguo-buccal directions using a resonance frequency analysis device (Osstell Beacon, Osstell, Göteborg, Sweden) with a single-use magnetic peg specific to the implant (SmartPeg Type 07, Osstell, Göteborg, Sweden).
The flap will be closed using non-resorbable monofilament sutures, and the implant will be submerged (two-stage protocol).
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* The area in which the implants will be placed must have had at least 6 months of healing;
* Residual alveolar ridge width ≥7 mm;
* Available bone height \>9 mm at the planned implant site;
* Patient aged \>18 years;
* Patient does not use any removable prosthesis at the site to be treated;
* Patient is able and willing to comply with the study protocol;
* Patient signs the written informed consent.
Exclusion Criteria
* Uncontrolled bleeding disorders;
* Uncontrolled diabetes (HBA1c \> 7.5);
* History of head and/or neck radiotherapy within the past 24 months;
* Immunocompromised patients, HIV positive, or undergoing chemotherapy within the past five years;
* Current or previous antiresorptive therapy;
* Psychological or psychiatric disorders;
* Drug or alcohol abuse.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Trieste
OTHER
International Piezosurgery Academy
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Trieste
Trieste, TS, Italy
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MEGAWH 1.0
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.